Our data provide a likely explanation as to why loss of Casp8 and low levels of Ripk1 can be driver mutations in certain types of cancer, leading to chromosome instability that may favor tumor evolution, heterogeneity, acquisition of drug resistance, and heightened risk for tumor relapse. The gene discussed is RIPK1; the disease is cancer.